Persson U - Search Results

1

A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing.

Persson U, Svensson J, Pettersson B. Persson U, et al. Appl Health Econ Health Policy. 2012 Jul 1;10(4):217-25. doi: 10.2165/11633930-000000000-00000. Appl Health Econ Health Policy. 2012. PMID: 22676213

2

Authors' reply to Godman and Gustafsson: "A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing".

Persson U, Svensson J, Pettersson B. Persson U, et al. Appl Health Econ Health Policy. 2013 Feb;11(1):83-4. doi: 10.1007/s40258-013-0009-1. Appl Health Econ Health Policy. 2013. PMID: 23359036 No abstract available.

3

Risk sharing in managed entry agreements-A review of the Swedish experience.

Andersson E, Svensson J, Persson U, Lindgren P. Andersson E, et al. Among authors: persson u. Health Policy. 2020 Apr;124(4):404-410. doi: 10.1016/j.healthpol.2020.02.002. Epub 2020 Feb 18. Health Policy. 2020. PMID: 32093981 Review.

4

Societal value of stem cell therapy in stroke--a modeling study.

Svensson J, Ghatnekar O, Lindgren A, Lindvall O, Norrving B, Persson U, Kokaia Z. Svensson J, et al. Among authors: persson u. Cerebrovasc Dis. 2012;33(6):532-9. doi: 10.1159/000337765. Epub 2012 May 9. Cerebrovasc Dis. 2012. PMID: 22571941

5

Multi-indication and Combination Pricing and Reimbursement of Pharmaceuticals: Opportunities for Improved Health Care through Faster Uptake of New Innovations.

Persson U, Norlin JM. Persson U, et al. Appl Health Econ Health Policy. 2018 Apr;16(2):157-165. doi: 10.1007/s40258-018-0377-7. Appl Health Econ Health Policy. 2018. PMID: 29470774

6

[Important to keep the principle of value-based pricing of drugs].

Persson U, Levin LA, Pettersson B. Persson U, et al. Lakartidningen. 2009 Oct 28-Nov 3;106(44):2862-4. Lakartidningen. 2009. PMID: 19967967 Swedish. No abstract available.

7

Drug and treatment costs in Parkinson's disease patients in Sweden.

Lökk J, Borg S, Svensson J, Persson U, Ljunggren G. Lökk J, et al. Among authors: persson u. Acta Neurol Scand. 2012 Feb;125(2):142-7. doi: 10.1111/j.1600-0404.2011.01517.x. Epub 2011 Apr 6. Acta Neurol Scand. 2012. PMID: 21470194

8

Reducing uncertainty in value-based pricing using evidence development agreements: the case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa®) in Sweden.

Willis M, Persson U, Zoellner Y, Gradl B. Willis M, et al. Among authors: persson u. Appl Health Econ Health Policy. 2010;8(6):377-86. doi: 10.2165/11531160-000000000-00000. Appl Health Econ Health Policy. 2010. PMID: 21043539

9

The End of the International Reference Pricing System?

Persson U, Jönsson B. Persson U, et al. Appl Health Econ Health Policy. 2016 Feb;14(1):1-8. doi: 10.1007/s40258-015-0182-5. Appl Health Econ Health Policy. 2016. PMID: 26112982

10

Value of treatment in clinical trials versus the real world: the case of abiraterone acetate (Zytiga) for postchemotherapy metastatic castration-resistant prostate cancer patients in Sweden.

Svensson J, Andersson E, Persson U, Edekling T, Ovanfors A, Ahlgren G. Svensson J, et al. Among authors: persson u. Scand J Urol. 2016 Aug;50(4):286-91. doi: 10.3109/21681805.2016.1172254. Epub 2016 Apr 25. Scand J Urol. 2016. PMID: 27109827

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

275 results

Search Page

Filters